NCT05578664View on ClinicalTrials.gov

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Oligometastatic Renal Cell Carcinoma
Interventions
DRUG

Pembrolizumab injection plus metastasis directed treatment (surgery or RT)

Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1

OTHER

Tumor resection or RT

Tumor resection or RT will be applied within 42 days from randomization.

Trial Locations (1)

00168

RECRUITING

"Fondazione Policlinico Universitario A. Gemelli IRCCS", Rome

All Listed Sponsors
lead

Consorzio Oncotech

OTHER